The Problem With "How Are You Feeling?"
Autoimmune blistering disease fluctuates. It flares and it settles, and it does both without asking anyone's permission and often without an obvious cause.
Which means that on any given day, "how are you feeling?" is close to useless as evidence about whether a treatment is working. Ask on a good day and everything is working. Ask on a bad day and nothing is. Ask a frightened person who has been taking something for eight weeks and paid for it, and you will get an answer shaped by hope rather than by the disease.
Every clinic in this field knows that, and a great many of them rely on it. A treatment assessed by asking the patient how they feel, at a moment of the clinic's choosing, will always look effective.
So here is what we measure instead, and when we are willing to draw a conclusion from it.
Leading Indicators
These move first. They are the only things worth looking at before month two, and all of them come from your daily diary.
Itch, zero to ten, once a day. In pemphigoid this is the most sensitive early instrument that exists. The itch commonly precedes any blister by months at the onset of the disease, and it tends to move before the blisters do on the way back down as well. An itch score falling while the blister count is unchanged is real information, and it is the earliest information you will get.
New lesions per day. New. Not total.
This distinction is the one people get wrong, and getting it wrong is why they conclude nothing is happening when something is. Total lesion count is a stock: it falls slowly even after the disease has quietened, because existing lesions heal at their own pace. New lesion formation is a flow, and the flow is what tells you what the disease is doing today.
In pemphigus, where blisters are flaccid and rupture almost immediately, count new erosions instead.
Erosion healing time. Mark one erosion. Record the day it opened and the day it closed. Days-to-closure is one of the earliest honest signals of change, because it does not depend on how much disease you have. A quietening disease heals what it has already made faster, usually before it stops making new ones.
Mucosal function. For pemphigus vulgaris — driven by antibodies against desmoglein 3, and usually beginning in the mouth — this is the most important line in the diary. Can you eat solids, softs, or only liquids? Can you brush your teeth? Is swallowing painful?
A decline here is not a data point to review at your next call. It is a reason to contact your dermatologist today.
Lagging Indicators
These move late. Judging the protocol by them at week six will always produce a false negative.
Total lesion burden. What you see in the mirror. It is the last thing to fall, for the reason given above.
Post-inflammatory pigmentation. Pemphigoid leaves marks that persist long after the disease that made them has gone quiet. Pigmentation is a history of the disease, not a measure of it, and reading it as a measure will mislead you in both directions.
ELISA titres. Anti-BP180 and anti-BP230 in pemphigoid; anti-desmoglein 1 and anti-desmoglein 3 in pemphigus. These track disease activity, and they are the closest thing to an objective number in this field.
They are also not ours. Your dermatologist orders them, interprets them, and acts on them. We ask you for them because a titre trend is genuinely informative, and because a protocol that ignored the only objective marker available would be indefensible. But we do not own that test, we do not draw conclusions from it alone, and we are not the people who should be acting on it.
The Gates
The point of a gate is to make continuing a decision rather than a default.
Without gates, a course of treatment simply continues until the patient runs out of money or belief, at which point they quietly stop and are never counted. That is the ordinary failure mode of this industry, and we have tried to design it out by fixing the dates in advance.
Week 6 — the movement check. Not an outcome check. Nobody is asking whether you are better; the first four to eight weeks of EPOH are internal work and no visible surface change is expected. The only question is whether any leading indicator has moved: itch, new-lesion rate, healing time. If one has, the phase work is engaging. If none has, that is noted and the formulation set is examined.
Week 12 — continue, modify, or stop. The first real decision. Continue if the leading indicators are moving. Modify if some are and some are not, or if adherence has been broken and we need one clean run at it. Stop if nothing has moved on good adherence — and stop is a genuine option here, not a formality mentioned to sound balanced.
Month 4 — the surface gate. Months two to four is the window in which disease begins to change on the surface in people who respond. If, at the end of month four, surface disease is unchanged or worse on good adherence, that is a stop signal, and we will say so rather than discovering a longer timeline.
Month 8 and beyond — sustained remission. We do not use that phrase before month eight, and you should distrust anyone who does. A relapsing disease is quiet often enough that three quiet weeks mean nothing. Eight months of a documented low-activity state is a different claim, and it is the only one we are prepared to make.
What We Deliberately Do Not Measure
How satisfied you are. It measures us, not the disease, and the two are only loosely related. People who like their clinician report better outcomes than they actually have.
Before-and-after photographs chosen by us. Any competent photographer can produce a striking pair from an unchanged patient by moving a lamp. This is why we ask for photographs on a fixed protocol — same room, same light, same distance, same sites, weekly, with a size reference in frame — and why the useful ones are always the boring ones.
Anything from the people who stopped. We do not collect it, because we cannot collect it honestly, and this is worth being blunt about.
The people who leave at week five are exactly the people any real assessment of this protocol would need to include, and they are exactly the people who do not answer a follow-up call. Every clinic in this field has that hole in its data. The only difference between them is whether they mention it.
Why This Does Not Produce a Success Rate
You will have noticed that none of the above yields a headline number, and we do not publish one. That is deliberate, and it has its own page.
Briefly: nearly every patient here is also on conventional treatment, correctly, which means a good outcome cannot be cleanly attributed to us. The disease fluctuates naturally, which means improvement is not the same thing as our improvement. And any honest denominator would have to include the people who quit, whom we cannot follow.
Any number we published would be a number we could not defend. We would rather have none than a dishonest one.
What This Gets You
A protocol in which the question "is this working?" has an answer that does not depend on how you happen to feel on the day somebody asks. A date on which that question gets asked. And a defined point at which the answer is permitted to be no.
That is a smaller offer than a success rate. It is also the only offer that survives contact with a disease that fluctuates.
